An Open Trial of Iloperidone for Mixed Episodes in Bipolar Disorder.
J Clin Psychopharmacol
; 37(5): 615-619, 2017 Oct.
Article
en En
| MEDLINE
| ID: mdl-28817490
ABSTRACT
BACKGROUND:
Mixed mood states in bipolar disorder are difficult to treat and when present indicate worse illness trajectories. Several medications are US Food and Drug Administration approved to treat mixed episodes; however, the clinical trials have been short term and rarely reported depression response.METHODS:
We conducted a 5-month open-label trial examining the tolerability and efficacy of iloperidone for bipolar disorder mixed episodes.RESULTS:
Mania and depression scores significantly improved over the course of the study for study completers (ie, 60%-68% improvement for manic symptoms and 41%-49% for depression symptoms). Improvements were observed early in the trial and after adjusting for concomitant medication effects. The average daily dose in completers was 15 mg. Thirty-nine percent (12/31) of the eligible sample discontinued early because of adverse effects. The adverse events most commonly associated with withdrawal were increased heart rate/palpitations (n = 5 of 12) and urinary incontinence/intense urge to urinate (n = 3 of 12).CONCLUSIONS:
In a subset of patients, iloperidone provides relief for classic manic, depression, and irritability symptoms associated with mixed episodes in a long-term trial. Adverse effect profiles are likely to be a major factor contributing to individualized medication use.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piperidinas
/
Trastorno Bipolar
/
Isoxazoles
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2017
Tipo del documento:
Article